FI81264B - MICROPARTICLAR OCH GASBLAOSOR INNEHAOLLANDE ULTRALJUDCONTRASTMELEL - Google Patents

Abstract

1. Contrast medium containing microparticles and gas bubbles for ultrasound diagnostics, characterised in that it contains microparticles of a solid surface-active substance, optionally in combination with microparticles of a non-surface-active solid, in a liquid carrier.

Description

1 81264

Ultrasonic contrast agent containing microparticles and gas bubbles

The invention relates to a contrast agent containing microparticles and gas bubbles for use in ultrasound diagnostics. The invention also relates to a package for the preparation of such a contrast agent.

Ultrasound examination of organs (sonography) is a diagnostic method that has been introduced and practiced for a few years. Ultrasonic waves in the mega-10 hertz range (above 2 megahertz at wavelengths between 1 and 0.2 mm) are reflected from the interfaces of different tissue species. The echoes thus formed are amplified and made visible. Of great importance in this case is the examination of the heart by this method, called eco-15 cardiography (Haft, JI et al .: Clinical echocardiography, Futura, Mount Kisco, New York 1978; Köhler, E. Klinische Echocardiography, Enke, Stuttgart 1979; Stefan , G. et al .: Echocardiography, Thieme, Stuttgart-New York 1981; G. Biamino, L. Lange Echocardiography, Hoechst 20 AG, 1983.)

Since fluids - including blood - only produce ultrasound shade when there are differences in density with the environment, opportunities were sought to make blood and its flow visible to ultrasound, which is also possible by adding tiny small gas bubbles.

Several methods for making and stabilizing gas bubbles are known in the literature. They can be produced, for example, by shaking or mixing strong solutions, such as saline solutions, dye solutions, or previously collected blood, before injecting them into the bloodstream.

. - Although this achieves an ultrasonic shadow effect, these methods have serious drawbacks in the form of poor reproducibility, variation in the size of the gas bubbles in the mouth and, due to the proportion of large gas bubbles of a visible size, in a certain plug. These disadvantages have been partially eliminated by other methods, cf. for example, U.S. Patent No. 3,640,271, which produces reproducibly sized bubbles by filtering or using 5 DC electrode arrangements. In this case, the advantage of the possibility of producing gas bubbles of reproducible size is offset by considerable technical costs.

U.S. Patent No. 4,276,885 describes a method of making gas bubbles of a certain size surrounded by a protective gelatin coating. The finished bubbles can only be stored in a frozen state, for example at a refrigerator temperature, in which case they must be brought back to body temperature for use.

U.S. Patent No. 4,265,251 describes the manufacture of solid shell gas bubbles of a certain size from saccharides, which gas bubbles may be filled with pressurized gas. If they are at normal pressure, they can be used as an ultrasonic contrast agent; when used with elevated internal pressure, they function in measuring blood pressure.

20 Although the storage of fixed gas bubbles does not present any problem, the technical costs of manufacture are a significant cost factor.

With the prior art contrast agents, the risks arise from two factors, namely the size and number of solid particles and gas bubbles.

Ultrasonic contrast agents manufactured to date have always had only a few of the required properties: 1.) Exclusion of the stopper 30 Gas bubbles (size and number) - Solid particles (size and number) 2.) Repeatability 3.) Sufficiently long stability 4.) Lung permeability e.g. to obtain ultrasonic shading of the left 35 halves of the heart 3 81264 5.) capillary permeability 6.) sterility and pyrogen-free of the preparation 7.) reasonably easy to prepare 5 8.) and trouble-free storage.

Admittedly, European Application Publication No. 52575 describes the manufacture of gas bubbles which meet the required properties. To prepare them, the micro-particles of a solid crystalline substance, such as galactose, are suspended in a carrier liquid, whereby the gas adsorbed on the surface of the particles is enclosed in the interparticle cavities or in the cavities inside the crystals, forming gas bubbles. The suspension of gas bubbles and microparticles thus formed is injected after 10 minutes. Although European Application Publication No. 52575 claims that a suspension prepared according to the method described is suitable for peripheral venous injection to appear in both the right half of the heart and through the lung after passing to the left half of the heart and for blood and its flow to be seen by sonication, this claim was not substantiated. Thus, it was found that the contrast agent prepared according to the method described in European Application Publication No. 52575 and injected into the peripheral vein did not produce any ultrasound echoes in the left half of the heart.

It was an object of the present invention to provide a contrast agent for ultrasound diagnostics capable of visualizing blood and its flow rates not only in the right half of the heart but also through the lung capillary tissue 30 after passing through the left half of the heart when administered intravenously. In addition, it should also be able to study blood flow through other organs such as the heart muscle, liver, spleen and kidneys.

The novel agents of the invention have all of the properties expected of such a contrast agent and 4,81264 are listed above.

The invention relates to a contrast agent containing microparticles and gas bubbles for ultrasonic diagnostics. The contrast agent is characterized in that it contains 0.01 to 10% by weight of microparticles of solid, surfactant, optionally together with microparticles of non-surfactant solid in a liquid carrier.

The invention also relates to a package for the preparation of an ultrasonic contrast agent comprising microparticles and 10 gas bubbles. The package is characterized in that it comprises a) a container with a volume of 5-10 ml, provided with a closure which allows the contents to be removed under sterile conditions, which container is filled with 4 ml of liquid carrier, and b) a second container with a volume of 5-10 ml, fitted with a closure to allow the contents to be removed or the mixture to be added under sterile conditions, which container is filled with microparticles of solid interfacial agent, optionally together with microparticles of non-interfacial solid, having an average particle size of <1 to 10 μm, the weight ratio of surfactant to any non-interfacial solid present being present being 0.01 to 5: 100 and the amount of microparticles being 5 to 50% by weight, preferably 9 to 10% by weight. 40% by weight.

Surprisingly, it has been found that suspending the microparticles of the solid interfacial agent, possibly together with the microparticles of the non-interfacial agent, in the carrier provides an ultrasound contrast agent which allows an ultrasound image to be reproduced in the peripheral venous artery. Thus, since the left half of the heart can be achieved with the ultrasound contrast agent according to the invention after intravenous administration, ultrasound shadows of 5 81264 organs maintained by the blood from the aorta are also possible after intravenous administration, e.g., myocardium, liver, spleen, kidney, e.g. It is self-evident that the ultrasound contrast agent according to the invention so-5 also serves as a contrast agent for the right half of the heart and for all other uses of ultrasound contrast agent.

Suitable interfacial agents for the preparation of microparticles are all substances which are physiologically acceptable in the amounts used, i.e.

10 have low toxicity and / or are biodegradable and have a melting point higher than room temperature. Particularly suitable are lecithin, lecithin fractions and derivatives, polyoksietyleeniras-fatty acid esters such as polyoxyethylene fatty alkoholieet-15 ether, polyoxyethylated sorbitan fatty acid ester, glyse-rine-polyetyleeniglykolioksistearaatti, glyseriinipoly-etyleeniglykolirisiinioleaatti, ethoxylated soijasteriini, ethoxylated castor oils and the hydrogenated derivatives thereof, cholesterol, polyoxyethylene fatty acid stearates and poly-20 oxyethylene polyoxypropylene polymers with molecular weights of 6800-8975, 13300 and 16250, sucrose esters such as sugar ester, e.g. sucrose palmitate and sucrose mono-laurate or sucrose glycerides such as C C20) fatty acids or their metal salts, polyoxyethylene fatty acid esters, mono-, di- and triglycerides, sorbitan fatty acid esters, sucrose fatty acid esters or fatty acid esters such as butyl stearate and ascorbyl lipalmitate, of which calcium stearate, sucrose esters of lauric acid, stearic acid and palmitic acid, and ascorbyl palmitate are preferred.

The interfacial agent is used in a concentration of 0.01 to 10% by weight, preferably 0.04 to 0.5% by weight.

If desired, the microparticles of the interfacial agent can be combined with the microparticles of the physiologically acceptable 6,81264 crystalline solid. In this case, organic and inorganic substances can be used, e.g. salts such as sodium chloride, sodium citrate, sodium acetate or sodium tartrate, monosaccharides such as glucose, fructose or galactose, disaccharides such as sucrose, lactose or maltose, noose or arthrosis such as arylose or cyclodextrins such as α, S- or γ-cyclodextrin, with galactose, lactose and α-cyclodextrin being preferred. They may be included in the substance according to the invention in a concentration of 5 to 50% by weight, preferably 9 to 40% by weight.

To prepare the microparticles, these materials are recrystallized under sterile conditions. Next, they are comminuted under sterile conditions, e.g., a flour-15 club in an air jet mill, until the desired particle size is reached. A particle size of <1 to 50, preferably 1 to 10, is achieved. The particle size is determined in suitable measuring devices. The microparticles produced consist either of a comminuted surfactant alone or of a mixture of interfacial microparticles and non-interfacial solid microparticles. In this case, the weight ratio of the solid interface to the non-interface is 0.01 to 5: 100.

Both the size of the micro-particles achieved by the comminution and also the size of the gas bubbles contained in the contrast medium according to the invention ensure the passage of harmless capillary vasculature and the capillary tissue of the lung and exclude the formation of plugs.

The gas bubbles required to form the shadow pass through the partially suspended microparticles, absorbed on the outer surface of the microparticles, in a cavity between the microparticles or enclosed in crystals.

The volume of gas carried by the microparticles in the form of gas bubbles is 0.02 to 0.6 ml per gram of microparticles. 35 In addition to the transport operation, the carrier liquid must have the function of stabilizing the suspension of microparticles and gas bubbles, e.g. in order to prevent the settling of the microparticles and the coalescence of the gas bubbles or to slow down the dissolution of the microparticles.

Suitable liquid carriers are water, aqueous solutions of one or more inorganic salts, such as physiological saline and buffer solutions, aqueous solutions of mono- or disaccharides, such as galactose, glucose or lactose, monohydric or polyhydric alcohols, if they are physiologically acceptable, such as ethanol, isopropyl alcohol, polyethylene glycol, ethylene glycol, glycerol, propylene glycol, propylene glycol methyl ester or aqueous solutions thereof.

Preferred are water and physiological electrolyte-15 solutions such as physiological saline and aqueous solutions of galactose and lactose. If solutions are used, the concentration of the solute is 0.1 to 30% by weight, preferably 0.5 to 25% by weight, in particular 0.9% aqueous saline or 20% aqueous galactose is used.

To prepare a ready-to-use ultrasound contrast agent, a sterile vehicle is added to a sterile solid surfactant in the form of microparticles, optionally combined with a non-surfactant, and the mixture is shaken until a homogeneous suspension is formed which requires immediate injection of about 5-10 seconds. after preparation, however, no later than 5 minutes thereafter as a bolus into a peripheral vein or a pre-made catheter at a dose of 0.01 ml per 1 ml / kg body weight.

For convenience, the components required for the preparation of the substance of the invention, such as the carrier liquid (A) and the interfacial microparticles, are optionally combined with the non-interfacial solid (B) microparticles to the extent necessary for the study 8 81264 in two separate containers. Both containers have stoppers that allow removal and insertion using a syringe under sterile conditions (vials). The size of the container B must be such that the contents of the container A can be transferred to the container B by means of a syringe and the combined components shaken.

Carrying out an ecocardiographic study on a 10 kg baboon demonstrates the use of a contrast agent according to the invention: 5 ml of carrier liquid (prepared according to Example 1A) is taken from a vial with a syringe and added to 2 g of microparticles (prepared according to Example IB) in another vial, and shaken for 15 5-10 s until a homogeneous suspension is formed.

2 ml of this suspension is injected into a peripheral vein (V. jugularis, brachialis or saphena) via a 3-way tap at an infusion rate of at least 1 ml / s, preferably 2-3 ml / s. The contrast injection involves the immediate injection of 10 ml of physiological saline at the same rate in order to maintain the contrast bolus as far as possible up to the right half of the heart. Before and after, as well as during the injection, a commercial ecocardiography of the sound head is held on the thorax of the test animal so as to obtain a typical cross-section through the left and right halves of the heart. This experimental arrangement is in accordance with the state of the art and is known to those skilled in the art.

If the ultrasound contrast agent reaches the right half of the heart, the 2-D sound image or M-mode sound image 30 can monitor how the blood marked by the contrast agent first reaches the correct atrial height, then the right ventricle and pulmonary artery, with homogeneous filling for about 10 s. While the cavities of the right half of the heart are again emptied on ultrasound, blood marked by the var-35 substance appears through the lungs after passing through the lungs.

II

9 81264 to the cholera veins, fills the left atrium, left ventricle, and aorta homogeneously, allowing the shadow to remain 2-3 times longer than in the right half of the heart. In addition to the image of the blood flow flowing in the cavities of the left half of the heart, 5 also shows an image of the myocardium reflecting back the flow.

However, the use of the ultrasound contrast agent of the invention is not limited to visualizing blood flow in the arterial portion of the heart after intravenous administration, but is also used with great success as a contrast agent in the study of the right half of the heart and other organs.

Example 1 A) Preparation of carrier liquid 80 g of galactose are dissolved in water for injection, made up to a volume of 400 ml, filtered through a 0.2 filter, 4 ml of this filtrate are filled into 5 ml flasks and sterilized for 20 minutes at 120 ° C.

B) Preparation of microparticles Under sterile conditions, 198 g of galactose are mixed with 2 g of magnesium stearate by homeopathic rubbing, sieved through a 0.8 mm sieve, mixed loose and ground in an air jet mill until the following particle size distribution is reached: 25 median 1.9 pm 99% <6 pm 90% <3 pm

The determination of the particle size and its distribution takes place in a particle measuring device after suspension in anhydrous isopropanol. The microparticles are each filled into 5 ml vials.

C) To prepare 5 ml of the ready-to-use ultrasound contrast agent, add the contents of the vial containing the carrier liquid (20% galactose solution in water, A) using a syringe 35 to the vial containing microparticles (B) and shake until a homogeneous suspension (5-10 seconds).

Example 2 A) Preparation of carrier liquid 5 Water used for spraying is used, each time filled into 4 ml 5 ml bottles and sterilized for 20 minutes at 120 ° C.

B) Preparation of microparticles

Under sterile conditions, 198 g of galact-10 toose are mixed with 2 g of ascorbyl palmitate by homeopathic massage with thorough care and further worked up as described in Example 1 (B) to give the following particle size distribution: median 1.9 μm 100% <6 μm 90% < 3 pm.

The determination of the particle size takes place as described in Example 1 under B).

The microparticles are each filled into 5 ml bottles. C) To prepare 4.5 ml of ready-to-use ultrasound contrast agent, add the contents of the carrier-liquid bottle (water, A) to the microparticle bottle (B) using a syringe and shake until a homogeneous suspension is formed (5-10 seconds).

25 Example 3 A) Preparation of a carrier liquid

Dissolve 4.5 g of sodium chloride in water to a volume of 500 ml, filter the solution through a 0.2 filter, pressurize 4 ml of this solution into 5 ml bottles and sterilize for 20 minutes at 120 ° C.

B) Preparation of microparticles

Under sterile conditions, 198 g of anhydrous lactose (<0.3 mm) are thoroughly mixed with 2 g of ascorbyl palmitate by homeopathic rubbing and the mixture is further treated as in Example 1, point B) to give 81264 g, giving the following particle size distribution: median 2, 8 μπι 100% <48 pm 99% <12 pm 5 The determination of the particle size is carried out as described in Example 1, point B).

The microparticles are each filled into 1.6 g 5 ml flasks.

C) To prepare 5 ml of ready-to-use ultrasound contrast agent, add the contents of the flask (0.9% sodium chloride solution in water, A) to the flask containing microparticles (B) using a syringe and shake until a homogeneous suspension is formed (5-10 seconds).

Example 4 15 A) Preparation of carrier liquid

As described in Example 3, A, a 0.9% aqueous solution of sodium chloride is prepared, filled in 4 ml portions into 5 ml flasks and sterilized for 20 minutes at 120 ° C.

20 B) Preparation of microparticles

Under sterile conditions, 199 g of α-cyclodextrin are mixed with 1 g of ascorbyl palmitate by thorough homepatic massage and the mixture is further treated as described in Example 1 (B) to give the following microparticles with a size distribution: median 2 μm 99% <6 μm 90% <4 pm

The determination of the particle size is carried out as described in Example 1 (B).

The microparticles were each filled into 400 mg 5 ml flasks.

C) To prepare 4 ml of ready-to-use ultrasound contrast agent, add the contents of the flask (0.9% aqueous sodium chloride solution 35. A) using a syringe to a flask containing microparticles (81) and shake until a homogeneous suspension is formed (5-10 seconds).

Example 5 A. Preparation of carrier liquid 5 50 g of lactose are dissolved in water for injection, made up to a volume of 500 ml, filtered through a 0.2 filter, each time filled into 4 ml 5 ml bottles and sterilized for 20 minutes at 120 ° C.

10 B. Preparation of microparticles

Ascorbyl palmitate is dissolved in methanol, sterile filtered through a 0.2 filter, recrystallized under sterile conditions, dried and sieved through a 0.8 mm sieve. Next, sterile 15 ascorbyl palmitate is ground under sterile conditions in an air-jet mill until the following particle size distribution is reached: median value 1.9 pm 99% <6 pm 20 90% <3 pm

The particle size and its distribution are determined in a particle measuring device after suspension in a 0.1% aqueous solution of Pluronic F68.

The microparticles are each filled into 40 mg sterile-25 vials in 5 ml bottles.

C. To prepare 4 ml of ready-to-use ultrasound contrast agent, add the contents of the vial containing the carrier liquid (10% lactose solution, A) to the vial containing the microparticles using a syringe and shake until a homogeneous suspension is formed.

Example 6 A. Preparation of carrier liquid

Dissolve 4.5 g of sodium chloride in 500 ml of water, filter the solution through a 0,2 filter at 35 pressure, make up to 4 ml with 5 ml each.

II

i3 81 264 flasks and sterilized for 20 minutes at 120 ° C.

B. Preparation of microparticles

Under sterile conditions, apply a sterile-filtered solution of 0,5 g of ascorbyl palmitate in 40 g of isoprop-5-panol to 199.5 g of sterile galactose particles, dry off the isopropanol at 40 ° C and 27 kPar and grind in an air jet mill until the following particle size is obtained. 1.9 pm 10 99% <6 pm 90% <3 pm

The particle size and its distribution are determined in a particle measuring device, e.g. after suspension in isopropanol. The microparticles are packaged in 5 ml 15 bottles of 2 g each.

C. To prepare 5 ml of ready-to-use ultrasound contrast medium, add the contents of the vial containing the carrier liquid (0.9% aqueous sodium chloride solution, A) to the microparticle flask (B) using a syringe and shake until a homogeneous suspension is formed (5-10 seconds).

Example 7 A. Preparation of carrier liquid

Dissolve 4.5 g of sodium chloride in water, make up to 500 ml, filter the solution through a 0.2 filter, make up to 4 ml with 5 ml bottles and sterilize for 20 minutes at 120 ° C.

B. Preparation of Microparticles Under sterile conditions, 199.5 g of galactose is rubbed into 0.5 g of ascorbyl palmitate, mixed thoroughly, sieved through a 0.8 mm sieve and ground in an air jet mill until the following particle size distribution is obtained: 35 81264 median value 1.9 μπι % <6 μπι 90% <3 μπι

The determination of the particle size and its distribution takes place in a particle measuring device, e.g. suspended in isopropanol. The microparticles are packaged in 5 ml bottles of 2 g each.

C. To prepare 5 ml of ready-to-use ultrasound contrast agent, add the contents of a vial of carrier liquid 10 (0.9% aqueous sodium chloride solution, A) to a vial of microparticles (B) using a syringe and shake until a homogeneous suspension is formed (5-10 seconds).

Example 8 15 A. Preparation of the carrier liquid Water for injection is used, 4 ml each is filled into 5 ml bottles and sterilized for 20 minutes at 120 ° C.

B. Preparation of Microparticles Under sterile conditions, 0.5 g of sucrose monopalmitate is ground into 199.5 g of galactose, mixed thoroughly, sieved through a 0.8 mm sieve and ground in an air jet mill until the following particle size distribution is reached: median value 1.9 μm min 99% <6 pm min 90% <3 pm

The determination of the particle size and its distribution takes place in a particle measuring device, e.g. suspended in isopropanol. The microparticles are packaged in 5 ml bottles of 2 g each.

C. To prepare 5 ml of ready-to-use ultrasound contrast agent, add the contents of the bottle containing the carrier liquid (sterile water for injections, A) with a syringe to the microparticles (B).

II

is 81264 into a flask and shake until a homogeneous suspension is formed (5-10 seconds).

Example 9 A. Preparation of carrier liquid 5 Water for injections is filled into 4 ml bottles of 5 ml each and sterilized for 20 minutes at 120 ° C.

B. Preparation of microparticles

Under sterile conditions, apply a sterile-filtered solution of 0,5 g of sucrose monopalmitate in 40 g of isopropanol to 199,5 g of sterile galactose particles, dry at 40 ° C and 27 kPa to remove isopropanol and grind in an air-jet mill until the following particle size distribution: 15 median value 1.9 pm min 99% <6 pm min 90% <3 pm

The particle size and its distribution are determined in a particle measuring device, e.g. suspended in isopropanol. The microparticles are packaged in 5 ml bottles of 2 g each.

C. To prepare 5 ml of ready-to-use ultrasound contrast agent, add the contents of the vial containing the carrier liquid (water for injection A) to the vial containing the microparticles (B) using a syringe and shake until a homogeneous suspension is formed (5-10 seconds).

Example 10 A. Preparation of Carrier Liquid Water for injection is filled into 4 ml bottles of 5 ml each and sterilized for 20 minutes at 120 ° C.

B. Preparation of microparticles

Under sterile conditions, a sterile-filtered solution of 0,5 g of sucrose monostearate in 40 g of iso 81264 propanol is applied to 199,5 g of sterile galactose particles, dried at 40 ° C and 27 kPa and the isopropanol is ground. with an air jet mill until the following particle size distribution is reached: 5 median value 1.9 pm min 99% <6 pm min 90% <3 pm

The particle size and its distribution are determined in a particle measuring device, e.g. suspended in isopropanol. The microparticles are packaged in 5 ml bottles, each with 2 g.

C. To prepare 5 ml of ready-to-use ultrasound contrast agent, add the contents of the vial containing the carrier liquid (water for injections, A) to the vial containing the microparticles (B) using a syringe and shake until a homogeneous suspension is formed (5-10 seconds).

Example 11 A. Preparation of Carrier Liquid Water for injection is used, each time filled into 4 ml 5 ml bottles and sterilized for 20 minutes at 120 ° C.

B. Preparation of microparticles

Under sterile conditions, 0.5 g of sucrose monostearate is rubbed into 199.5 g of galactose, mixed thoroughly, sieved through a 0.8 mm sieve and ground in an air jet mill until the following particle size distribution is obtained: median value: 1.9 pm 30 min 99% <6 pm min 90% <3 pm

The particle size and its distribution are determined with a particle measuring device, e.g. suspended in isopropanol. The microparticles are packaged in 5 ml bottles in increments of 2 g.

To prepare 5 ml of ready-to-use ultrasound contrast agent, add the contents of the carrier liquid bottle (sterile water for injections, A) to the microparticle bottle 5 (B) using a syringe and shake until a homogeneous suspension (5-10 seconds) is formed.

Example 12 A. Preparation of carrier liquid

Fill 10 ml of water for injections into 4 ml bottles of 5 ml each and sterilize for 20 minutes at 120 ° C.

B. Preparation of microparticles

Under sterile conditions, apply a sterile-filtered solution of 0,5 g of sucrose distearate in 40 g of isopropane to 199,5 g of sterile galactose particles, dry at 40 ° C and 27 kPa in isopropanol and grind in an air-jet mill until the following is obtained. particle size distribution: median value: 1.9 pm 20 min 99% <6 pm min 90% <3 pm

The particle size and its distribution are determined in a particle measuring device, e.g. suspended in isopropanol. The microparticles are packaged in 5 ml bottles of 25 g each.

C. To prepare 5 ml of ready-to-use ultrasound contrast agent, add the contents of the vehicle fluid bottle (water for injections, A) to the microparticle bottle (B) using a syringe and shake until a homogeneous suspension (5-10 seconds) is formed.

Example 13 A. Preparation of carrier liquid Water for injection is used, each time 4 ml are filled into 5 ml flasks and these are sterilized at 81264 τ for 20 minutes at 120 ° C.

B. Preparation of microparticles Under sterile conditions, rub 0,5 g of precipitate rosacid stearate into 199,5 g of galactose, mix thoroughly, sieve through a 0,8 mm sieve and grind with an air jet mill until the following particle size distribution is obtained: median value: 1,9 μm min 99% <6 pm 10 min 90% <3 pm

The particle size and its distribution are determined in a particle measuring device, e.g. suspended in isopropanol. The microparticles are packaged in 5 ml bottles of 2 g each.

15 C. To prepare 5 ml of reconstituted ultrasound contrast medium, add the contents of the vehicle fluid bottle (sterile water for injections, A) to the microparticle bottle (B) using a syringe and shake until a homogeneous suspension (5-10 seconds) is formed.

Claims (15)

1. Contrast agent containing microparticles and gas bubbles for ultrasonic diagnostics, characterized in that it contains 0.01-10% by weight microparticles of a solid, cross-surfactant, optionally in combination with microparticles of a non-pertussive solid in a liquid carrier. 2. Agent according to claim 1, characterized in that it contains as a solid interface active substance lecithin, polyoxyethylene fatty acid ester, glycerine polyethylene glycol ricinoleate, cholesterol, polyoxyethylene polyoxy propylene polymers, sucrose acetate or sucrose ester, xyloge , saturated or unsaturated (C4-C20) fatty acids or metal salts thereof, polyoxyethylene fatty acid esters, mono-, di- and triglycerides or fatty acid esters as microparticles. Agent according to claims 1 or 2, characterized in that it contains magnesium stearate, ascorbyl palmitate, sucrose monopalmitate, sucrose monostearate or sucrose distearate as a solid surfactant in the form of microparticles in a concentration of 0.01-5% by weight. , 04-1% by weight. 4. Agent according to claim 1, characterized in that the microparticles present as a non-interfacing solid optionally contain cyclodextrin, monosaccharide, disaccharide, trisaccharide, polyols or inorganic or organic salts with a concentration of 5- 50% by weight. 5. An agent according to claims 1 or 4, characterized in that the non-cross-surfactant solid present contains galactose, lactose or α-cyclodextrin as microparticles at a concentration of 5-50% by weight, preferably 9-40%. weight-%. 35 li 23 81 264 6. Agent according to claim 1, characterized in that it contains as a physiologically acceptable carrier material water, physiological electrolyte solution, an aqueous solution of mono- or polyhydric alcohols such as glycerine, polyethylene glycol or propylene glycol methyl ester or an aqueous solution of a mono or disaccharide. 7. An agent according to claims 1 or 6, characterized in that it contains as a physiologically acceptable liquid carrier material water, physiologically saline, 10%: aqueous lactose or 20% aqueous galactose. 8. Agent according to claim 1, characterized in that it contains microparticles of magnesium stearate and galactose in a 20% aqueous galactose. An agent according to claim 1, characterized in that it contains microparticles of ascorbyl palmitate and galactose in water. An agent according to claim 1, characterized in that it contains microparticles of ascorbyl palmitate and α-cyclodextrin in a physiological saline solution. Agent according to claim 1, characterized in that it contains microparticles of ascorbyl palmitate in a 10% aqueous lactose solution. 12. Agent according to claim 1, characterized in that it contains microparticles of sucrose monopalmitate and galactose in water. Agent according to claim 1, characterized in that it contains microparticles of sucrose monostearate and galactose in water. 14. An agent according to claim 1, characterized in that it contains microparticles of sucrose distearate and galactose in water. 35 Packaging for producing an ultrasonic contrast agent containing microparticles and gas bubbles, characterized in that it comprises a) a container having a volume of 5-10 ml and provided with a closure means, which allows for withdrawal of the contents under sterile conditions, and which container is filled with 4 ml of a liquid carrier, and b) a second container which has a volume of 5-10 ml and is provided with a closure means which allows the contents to be withdrawn. or supply of a substance mixture under sterile conditions, and which container is filled with microparticles of a solid, interfacial agent, optionally in combination with microparticles of a non-pesticide solid having an average particle size of <1 -10 µm, wherein the weight ratio of the surfactant to the possibly present non-surfactant solid is 0.01-5: 100 and the amount of microparticle clear is 5-50 wt%, preferably 9-40 wt%. li